Decreased levels of active SMAD2 correlate with poor prognosis in gastric cancer

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Wu, Yijun ^a   Li, Qi ^b   Zhou, Xinhui ^a   Yu, Jiren ^a   Mu, Yunchuan ^a   Munker, Stefan ^b   Xu, Chengfu ^a   Shen, Zhe ^a   Müllenbach, Roman ^b,c   Liu, Yan ^b   Li, Li ^b   Gretz, Norbert ^b   Zieker, Derek ^d   Li, Jun ^d   Matsuzaki, Kouichi ^e   Li, Youming ^a   Dooley, Steven ^b   Weng, Honglei ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; MESSENGER RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; ACTA2 PROTEIN, HUMAN; ACTIN;

ADULT; ARTICLE; CANCER CELL; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; ADENOCARCINOMA; AGED; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; STOMACH TUMOR;

ACTINS; ADENOCARCINOMA; AGED; COLLAGEN TYPE I; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; SMAD2 PROTEIN; SMAD3 PROTEIN; STOMACH NEOPLASMS;

EID: 84859984312     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035684     Document Type: Article

References (44)

1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M, (2005) Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366: 1784-1793.
2. Wu WK, Cho CH, Lee CW, Fan D, Wu K, et al. (2010) Dysregulation of cellular signaling in gastric cancer. Cancer Lett 295: 144-153.
3. Moustakas A, Souchelnytskyi S, Heldin CH, (2001) Smad regulation in TGF-beta signal transduction. J Cell Sci 114: 4359-4369.
4. Shi Y, Massague J, (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
5. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, et al. (1997) TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 272: 27678-27685.
6. Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, et al. (1997) Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 272: 28107-28115.
7. Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, et al. (2009) Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer. Cancer Res 69: 5321-5330.
8. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, et al. (2007) Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46: 48-57.
9. Meulmeester E, Ten Dijke P, (2011) The dynamic roles of TGF-beta in cancer. J Pathol 223: 205-218.
10. Yang L, Moses HL, (2008) Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res 68: 9107-9111.
11. Kalluri R, Weinberg RA, (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
12. Ikushima H, Miyazono K, (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415-424.
13. Tang B, Yoo N, Vu M, Mamura M, Nam JS, et al. (2007) Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 67: 8643-8652.
14. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
15. Li X, Yue ZC, Zhang YY, Bai J, Meng XN, et al. (2008) Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. J Clin Lab Anal 22: 164-171.
16. Zhang Y, Liu B, Jin M, Ni Q, Liang X, et al. (2009) Genetic polymorphisms of transforming growth factor-beta1 and its receptors and colorectal cancer susceptibility: a population-based case-control study in China. Cancer Lett 275: 102-108.
17. Lin Y, Kikuchi S, Obata Y, Yagyu K, (2006) Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J Gastroenterol Hepatol 21: 432-437.
18. Matsuzaki K, (2011) Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res.
19. Matsuzaki K, (2011) Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis 32: 1578-1588.
20. Matsuzaki K, Okazaki K, (2006) Transforming growth factor-beta during carcinogenesis: the shift from epithelial to mesenchymal signaling. J Gastroenterol 41: 295-303.
21. Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Tahashi Y, et al. (2009) Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 49: 1203-1217.
22. Yamagata H, Matsuzaki K, Mori S, Yoshida K, Tahashi Y, et al. (2005) Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res 65: 157-165.
23. Fukuchi M, Nakajima M, Miyazaki T, Masuda N, Osawa H, et al. (2006) Lack of activated Smad2 in transforming growth factor-beta signaling is an unfavorable prognostic factor in patients with esophageal squamous cell carcinoma. J Surg Oncol 94: 51-56.
24. Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, et al. (2010) Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene 29: 1351-1361.
25. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, et al. (2002) Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 62: 497-505.
26. Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M, (2003) Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 9: 302-312.
27. Hoot KE, Oka M, Han G, Bottinger E, Zhang Q, et al. (2010) HGF upregulation contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion. J Clin Invest 120: 3606-3616.
28. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, et al. (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11: 147-160.
29. Shinto O, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, et al. (2010) Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer 10: 652.
30. Brown KA, Pietenpol JA, Moses HL, (2007) A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 101: 9-33.
31. Ju W, Ogawa A, Heyer J, Nierhof D, Yu L, et al. (2006) Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol Cell Biol 26: 654-667.
32. Uemura M, Swenson ES, Gaca MD, Giordano FJ, Reiss M, et al. (2005) Smad2 and Smad3 Play Different Roles in Rat Hepatic Stellate Cell Function and {alpha}-Smooth Muscle Actin Organization. Mol Biol Cell.
33. Zhu Y, Richardson JA, Parada LF, Graff JM, (1998) Smad3 mutant mice develop metastatic colorectal cancer. Cell 94: 703-714.
34. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, et al. (1999) Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol 19: 2495-2504.
35. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, et al. (2006) Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res 66: 828-838.
36. Sodir NM, Chen X, Park R, Nickel AE, Conti PS, et al. (2006) Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res 66: 8430-8438.
37. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, et al. (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18: 1280-1291.
38. Han SU, Kim HT, Seong DH, Kim YS, Park YS, et al. (2004) Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene 23: 1333-1341.
39. Kalluri R, Neilson EG, (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784.
40. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP, (2004) Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 23: 1155-1165.
41. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, et al. (2010) Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer 102: 844-851.
42. Warneke VS, Behrens HM, Hartmann JT, Held H, Becker T, et al. (2011) Cohort Study Based on the Seventh Edition of the TNM Classification for Gastric Cancer: Proposal of a New Staging System. J Clin Oncol 29: 2364-2371.
43. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, et al. (2003) p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38: 879-889.
44. Sekimoto G, Matsuzaki K, Yoshida K, Mori S, Murata M, et al. (2007) Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res 67: 5090-5096.